We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Lilly's Olumiant Succeeds in Another Late-Stage Eczema Study
Read MoreHide Full Article
Eli Lilly and Company (LLY - Free Report) and partner Incyte’s (INCY - Free Report) oral JAK inhibitor, Olumiant (baricitinib) met the primary endpoint in a phase III study evaluating it as a monotherapy in moderate-to-severe atopic dermatitis (“AD”), a type of eczema.
Top-line data from the BREEZE-AD5 study showed that 16-week treatment with 2mg dose of Olumiant met the primary endpoint of at least 75% improvement in skin inflammation, measured by Eczema Area and Severity Index (“EASI”), from baseline. BREEZE-AD5, conducted in North America, evaluated 1-mg and 2-mg doses of Olumiant as a monotherapy in AD patients.
The higher dose of the drug also met a key secondary endpoint of another measure of skin inflammation defined by clear or almost clear skin and at least 2 points improvement in the validated Investigator's Global Assessment for AD. This marks the fifth successful completion of a late-stage study evaluating Olumiant in AD patients.
Detailed data from the study will be presented at future scientific conferences and published in peer-reviewed journals. Lilly has already submitted a regulatory application seeking approval for label expansion of Olumiant to treat AD patients in Europe. Data from the BREEZE-AD5 study will support a supplemental new drug application or sNDA submission to the FDA for a similar label expansion of the drug.
The company previously completed successfully four phase III AD studies – BREEZE-AD1, BREEZE-AD2, BREEZE-AD4 and BREEZE-AD7. While 2mg and 4mg dosages of Olumiant met the primary endpoint of BREEZE-AD1 and BREEZE-AD2 studies, only 4mg dose of the drug met the primary endpoint in BREEZE-AD7 study. Earlier this week, the company reported data from BREEZE-AD4 study that demonstrated 4mg of Olumiant plus topical corticosteroids achieved at least 75% improvement in EASI from baseline after 16 weeks of treatment.
In the past year, shares of Lilly have gained 19% compared with the industry's increase of 12.4%.
Olumiant is one of the drugs in Lilly’s new pharmaceutical product portfolio, which is anticipated to be a key top-line driver going ahead. The drug generated $426.9 million in 2019, up more than 110% year over year mainly driven by upbeat sales in Europe.
Lilly is also developing Olumiant as a treatment for systemic lupus erythematosus and alopecia areata in mid-to-late stage studies.
Meanwhile, competition is on the rise in the JAK inhibitor segment as well as the eczema market. Regeneron Pharmaceuticals and Sanofi’s Dupixent is approved for treating AD since 2017 while AbbVie (ABBV - Free Report) and Pfizer (PFE - Free Report) are developing their respective candidates for the indication in late-stage studies.
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
Image: Bigstock
Lilly's Olumiant Succeeds in Another Late-Stage Eczema Study
Eli Lilly and Company (LLY - Free Report) and partner Incyte’s (INCY - Free Report) oral JAK inhibitor, Olumiant (baricitinib) met the primary endpoint in a phase III study evaluating it as a monotherapy in moderate-to-severe atopic dermatitis (“AD”), a type of eczema.
Top-line data from the BREEZE-AD5 study showed that 16-week treatment with 2mg dose of Olumiant met the primary endpoint of at least 75% improvement in skin inflammation, measured by Eczema Area and Severity Index (“EASI”), from baseline. BREEZE-AD5, conducted in North America, evaluated 1-mg and 2-mg doses of Olumiant as a monotherapy in AD patients.
The higher dose of the drug also met a key secondary endpoint of another measure of skin inflammation defined by clear or almost clear skin and at least 2 points improvement in the validated Investigator's Global Assessment for AD. This marks the fifth successful completion of a late-stage study evaluating Olumiant in AD patients.
Detailed data from the study will be presented at future scientific conferences and published in peer-reviewed journals. Lilly has already submitted a regulatory application seeking approval for label expansion of Olumiant to treat AD patients in Europe. Data from the BREEZE-AD5 study will support a supplemental new drug application or sNDA submission to the FDA for a similar label expansion of the drug.
The company previously completed successfully four phase III AD studies – BREEZE-AD1, BREEZE-AD2, BREEZE-AD4 and BREEZE-AD7. While 2mg and 4mg dosages of Olumiant met the primary endpoint of BREEZE-AD1 and BREEZE-AD2 studies, only 4mg dose of the drug met the primary endpoint in BREEZE-AD7 study. Earlier this week, the company reported data from BREEZE-AD4 study that demonstrated 4mg of Olumiant plus topical corticosteroids achieved at least 75% improvement in EASI from baseline after 16 weeks of treatment.
In the past year, shares of Lilly have gained 19% compared with the industry's increase of 12.4%.
Olumiant is one of the drugs in Lilly’s new pharmaceutical product portfolio, which is anticipated to be a key top-line driver going ahead. The drug generated $426.9 million in 2019, up more than 110% year over year mainly driven by upbeat sales in Europe.
Lilly is also developing Olumiant as a treatment for systemic lupus erythematosus and alopecia areata in mid-to-late stage studies.
Meanwhile, competition is on the rise in the JAK inhibitor segment as well as the eczema market. Regeneron Pharmaceuticals and Sanofi’s Dupixent is approved for treating AD since 2017 while AbbVie (ABBV - Free Report) and Pfizer (PFE - Free Report) are developing their respective candidates for the indication in late-stage studies.
Eli Lilly and Company Price
Eli Lilly and Company price | Eli Lilly and Company Quote
Zacks Rank
Lilly currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>